02496 友芝友生物－Ｂ
按盘价 
4.210 0.000 (0.000%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -34.277% | -63.429% | -75.096% | -74.201% |
| 股东资金回报率 (%) | -123.395% | -135.222% | -126.312% | -103.740% |
| 资本运用回报率 (%) | -119.450% | -149.997% | -121.160% | -103.680% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 78.904% | N/A | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -83.028% | N/A | N/A | N/A |
| 税前边际利润率 (%) | -90.526% | N/A | N/A | N/A |
| 纯利率 (%) | -90.526% | N/A | N/A | N/A |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 1.189 X | 1.439 X | 1.626 X | 2.208 X |
| 速动比率 (X) | 1.166 X | 1.406 X | 1.554 X | 2.051 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 88.600% | 57.678% | 48.527% | 28.473% |
| 总债项 / 总资产比率 (%) | 47.548% | 29.876% | 25.317% | 14.229% |
| 净债项 / 总资产比率 (%) | 0.403% | -35.332% | -25.377% | -27.281% |
| 总债项 / 股东资金比率 (%) | 417.075% | 70.592% | 49.184% | 19.893% |
| 长期债项 / 股东资金比率 (%) | 167.585% | 0.118% | 0% | 0.058% |
| 净债项 / 股东资金比率 (%) | 3.534% | -83.483% | -49.301% | -38.142% |
| 净现金 / (债项) ($) | (1.08百万) | 1.07亿 | 7.69千万 | 5.46千万 |
| 每股净现金 / (债项) ($) | (0.013) | 0.550 | -- | -- |
| 总债项 / 资本运用比率 (%) | 155.867% | 70.510% | 49.184% | 19.882% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 80.482日 | -- | -- | -- |
| 应收贸易帐周转率日数 (日) | 173.026日 | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 16.030日 | N/A | N/A | N/A |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -97,599,000 |
| 增长率 | -49.088% |
| 每股盈利/(亏损) | RMB -0.500 |
| 每股账面资产净值 (¥) | RMB 0.371 |